cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30640056.v1
title: Knowledge of the human papilloma virus and acceptance of its vaccine among male and female young adults in Jeddah, Saudi Arabia: A cross-sectional study

description: This study assessed university students’ awareness and knowledge of human papillomavirus (HPV) and its vaccine and willingness to accept vaccination in Jeddah, Saudi Arabia, and identified factors associated with these outcomes. This cross-sectional study was conducted in Jeddah, Saudi Arabia. The study population included university-level male and female students. During the first term of the 2023–2024 academic year, eligible participants were sent an online questionnaire. The study variables included measures of sociodemographic factors, awareness and knowledge of HPV and its vaccine, and vaccine acceptance. We conducted descriptive analysis of awareness, good knowledge, and willingness to accept vaccination, and multivariable logistic regression analyses to determine predictors of these outcomes. The study included 400 participants with a mean age of 21.4years, predominantly female and of Saudi nationality (93%). Awareness of HPV infection was reported by 49.3% of participants, while 44% were aware of the HPV vaccine. Among those aware of HPV, 82.2% recognized its link to cervical cancer, but misconceptions about HPV exist. Only 3.8% of participants had been vaccinated for HPV, and 33.5% expressed willingness to accept the vaccine. Age (per 1year increment; OR: 1.42, 95% CI: 1.25 to 1.62, <i>P</i> &lt; .001), mother’s education level (doctorate or advanced degree vs. pre-high school; OR: 4.65, 95% CI: 1.51 to 14.32, <i>P </i>= .007), and COVID-19 vaccine (received 3 doses vs.&lt;3; OR: 3.12, 95% CI: 1.78 to 5.45, <i>P</i> &lt; .001) were significant predictors of better HPV awareness. Living abroad was significantly associated with higher HPV vaccination rates (OR: 4.39, 95% CI: 1.27 to 15.1, <i>P </i>= .02). Male students were less likely to be willing to accept vaccination than females (OR: 0.38, 95% CI: 0.20 to 0.72, <i>P</i> = .003). HPV awareness, knowledge, and vaccine acceptance remain low among Saudi university students, with very limited uptake. Older age, maternal education, and prior COVID-19 vaccination were key predictors of awareness, highlighting important targets for future public health strategies. Targeted university-based and digital interventions are urgently needed to address these gaps and support national and regional HPV vaccination strategies. Future research should evaluate the effectiveness of such interventions and explore cultural and gender-specific barriers to HPV vaccine uptake.
DOI: 10.6084/m9.figshare.31018435
title: The vaccination status and attitudes toward human papillomavirus among gynecologists in China: A cross-sectional survey

description: Gynecologists are the main group promoting vaccines. Previous studies have paid less attention to their human papillomavirus(HPV) vaccination status.Understanding their acceptance and true attitudes toward vaccines, as well as the reasons for not getting vaccinated, is of great significance for promoting vaccines. A cross-sectional survey was conducted from June to August 2024 across six Chinese cities by the Cancer Endocrinology Committee of the Chinese Anti-Cancer Association, using a convenience sampling strategy to distribute questionnaires to gynecologists in tertiary public hospitals. Results were presented as case numbers (percentages), with group comparisons made using either the χ<sup>2</sup> test or Fisher’s exact probability method; influencing factors were analyzed via logistic regression. Out of 577 collected questionnaires, 563 were valid. The vaccination rate among female gynecologists was 46.07% (223/484), with the quadrivalent HPV vaccine being most common at 40.36%. The primary reason for not vaccinating was exceeding age limits, followed by male gender. And 12.35% of gynecologists were reluctant to vaccinate due to annual cervical cancer screening. 83.13% (468/563) gynecologists supported male vaccination.The level of support for vaccinating underage daughters was significantly higher than that for sons (87.74% vs. 68.92%, p&lt;.001). It is essential to enhance public awareness of the protective benefits of HPV vaccination for males and its efficacy in preventing various diseases beyond cervical cancer.
DOI: 10.6084/m9.figshare.31018435.v1
title: The vaccination status and attitudes toward human papillomavirus among gynecologists in China: A cross-sectional survey

description: Gynecologists are the main group promoting vaccines. Previous studies have paid less attention to their human papillomavirus(HPV) vaccination status.Understanding their acceptance and true attitudes toward vaccines, as well as the reasons for not getting vaccinated, is of great significance for promoting vaccines. A cross-sectional survey was conducted from June to August 2024 across six Chinese cities by the Cancer Endocrinology Committee of the Chinese Anti-Cancer Association, using a convenience sampling strategy to distribute questionnaires to gynecologists in tertiary public hospitals. Results were presented as case numbers (percentages), with group comparisons made using either the χ<sup>2</sup> test or Fisher’s exact probability method; influencing factors were analyzed via logistic regression. Out of 577 collected questionnaires, 563 were valid. The vaccination rate among female gynecologists was 46.07% (223/484), with the quadrivalent HPV vaccine being most common at 40.36%. The primary reason for not vaccinating was exceeding age limits, followed by male gender. And 12.35% of gynecologists were reluctant to vaccinate due to annual cervical cancer screening. 83.13% (468/563) gynecologists supported male vaccination.The level of support for vaccinating underage daughters was significantly higher than that for sons (87.74% vs. 68.92%, p&lt;.001). It is essential to enhance public awareness of the protective benefits of HPV vaccination for males and its efficacy in preventing various diseases beyond cervical cancer.
DOI: 10.6084/m9.figshare.30865129
title: Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

description: Developing a more effective seasonal influenza vaccine is necessary to reduce the global health and economic burdens caused by influenza virus infections. Next-generation influenza vaccines using computationally optimized broadly reactive antigen (COBRA) methodology elicit protective immune responses against strains over multiple seasons. Most influenza virus vaccines are currently administered intramuscularly and elicit systemic immune responses. Intranasal administration elicits mucosal immune responses at the site of infection, as well as systemic immunity. It was hypothesized that COBRA-derived hemagglutinin and/or neuraminidase recombinant protein combined with the c-di-AMP adjuvant will elicit broadly reactive mucosal and systemic immune responses when administered intranasally against seasonal influenza viruses in mice and ferrets that were pre-immune to influenza viruses. Multivalent COBRA-based antigens were formulated with c-di-AMP adjuvant and administered intranasally. Animals were vaccinated with either a trivalent COBRA H1, H3, and influenza B rHA vaccine, bivalent COBRA N1 and N2 rNA, or a pentavalent mixture of COBRA rHA and rNA antigens. Mice and ferrets vaccinated with COBRA rHA proteins had sera with HAI activity against a panel of influenza A and B strains isolated from multiple seasons. Vaccines containing rHA in the formulation had less weight loss and viral lung titers compared to animals vaccinated with rNA only or mock vaccinated animals following challenge. Pentavalent COBRA HA and NA vaccines delivered intranasally were the most effective vaccine combination tested with the broadest protective immunity against drifted seasonal influenza viruses.
DOI: 10.6084/m9.figshare.30865129.v1
title: Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

description: Developing a more effective seasonal influenza vaccine is necessary to reduce the global health and economic burdens caused by influenza virus infections. Next-generation influenza vaccines using computationally optimized broadly reactive antigen (COBRA) methodology elicit protective immune responses against strains over multiple seasons. Most influenza virus vaccines are currently administered intramuscularly and elicit systemic immune responses. Intranasal administration elicits mucosal immune responses at the site of infection, as well as systemic immunity. It was hypothesized that COBRA-derived hemagglutinin and/or neuraminidase recombinant protein combined with the c-di-AMP adjuvant will elicit broadly reactive mucosal and systemic immune responses when administered intranasally against seasonal influenza viruses in mice and ferrets that were pre-immune to influenza viruses. Multivalent COBRA-based antigens were formulated with c-di-AMP adjuvant and administered intranasally. Animals were vaccinated with either a trivalent COBRA H1, H3, and influenza B rHA vaccine, bivalent COBRA N1 and N2 rNA, or a pentavalent mixture of COBRA rHA and rNA antigens. Mice and ferrets vaccinated with COBRA rHA proteins had sera with HAI activity against a panel of influenza A and B strains isolated from multiple seasons. Vaccines containing rHA in the formulation had less weight loss and viral lung titers compared to animals vaccinated with rNA only or mock vaccinated animals following challenge. Pentavalent COBRA HA and NA vaccines delivered intranasally were the most effective vaccine combination tested with the broadest protective immunity against drifted seasonal influenza viruses.
DOI: 10.6084/m9.figshare.28228820
title: Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China

description: Patients receiving methadone maintenance treatment (MMT) elicited poor response and rapid anti-HBs loss after standard hepatitis B vaccination. An optimal hepatitis B vaccination was urgent. A randomized, parallel-controlled trial was conducted in patients receiving MMT from 2019 to 2020, and patients were randomized to receive 3 or 4 doses of 20 or 60 µg of hepatitis B vaccine. Follow-up was extended to 2021, for assessment of 1-year persistence of immunogenicity at month 18. A total of 145 participants completed the 1-year follow-up. From month 7 to 18, the response rates of the IM60 × 4 group, IM20 × 4 group, and IM20 × 3 group decreased from 95.52% (64/67) to 84.09% (37/44), 94.67% (71/75) to 78.72% (37/47), and 89.19% (66/74) to 68.52% (37/54), respectively. No significant differences were observed in the persistence of vaccine-induced responses among the three groups (<i>p</i> = .204). All three hepatitis B vaccine regimens demonstrated comparable declines in anti-HBs levels, with a rapid decrease observed within 1-year of follow-up. ClinicalTrials.gov (NCT03962816).https://clinicaltrials.gov/ct2/show/NCT03962816
DOI: 10.6084/m9.figshare.28228820.v1
title: Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China

description: Patients receiving methadone maintenance treatment (MMT) elicited poor response and rapid anti-HBs loss after standard hepatitis B vaccination. An optimal hepatitis B vaccination was urgent. A randomized, parallel-controlled trial was conducted in patients receiving MMT from 2019 to 2020, and patients were randomized to receive 3 or 4 doses of 20 or 60 µg of hepatitis B vaccine. Follow-up was extended to 2021, for assessment of 1-year persistence of immunogenicity at month 18. A total of 145 participants completed the 1-year follow-up. From month 7 to 18, the response rates of the IM60 × 4 group, IM20 × 4 group, and IM20 × 3 group decreased from 95.52% (64/67) to 84.09% (37/44), 94.67% (71/75) to 78.72% (37/47), and 89.19% (66/74) to 68.52% (37/54), respectively. No significant differences were observed in the persistence of vaccine-induced responses among the three groups (<i>p</i> = .204). All three hepatitis B vaccine regimens demonstrated comparable declines in anti-HBs levels, with a rapid decrease observed within 1-year of follow-up. ClinicalTrials.gov (NCT03962816).https://clinicaltrials.gov/ct2/show/NCT03962816
DOI: 10.6084/m9.figshare.30894074
title: Hospital burden of Respiratory Syncytial Virus in children in Spain (2016–2022): A retrospective study

description: Respiratory Syncytial Virus (RSV) is a leading cause of acute lower respiratory tract infections, particularly in children under two years of age. This study aimed to estimate the population-based burden of RSV-related hospitalizations in individuals under 19 y in Spain from 2016 to 2022. A retrospective analysis was conducted using national hospital discharge data. Hospitalization rates, mortality, case fatality, and associated healthcare costs were analyzed by age group and year. A total of 166,046 RSV-related hospitalizations were recorded (57.36% male), with 94.60% in children under 5 y and 66.22% in infants under 1 y. The highest mean hospitalization rate was observed in infants &lt;1 y (4,367.87 per 100,000), increasing to 5882.06 in 2022. Mortality was highest in infants &lt;1 y (2.9 per 100,000), while the highest case fatality rates occurred in the 10–14 (0.89%) and 15–19 (0.92%) age groups. Children &lt;5 y with comorbidities had significantly higher case fatality (0.76%) compared to those without (0.02%; OR=31.76). Hospitalization and mortality rates were lowest during the COVID-19 pandemic years. The mean cost per hospitalization was €3,169.63 for children &lt;5 y and €3,276.50 for infants &lt;1 y. The total cost exceeded €497 million, with €360 million attributed to infants &lt;1 y. RSV imposes a substantial burden on the pediatric population in Spain, particularly among infants. These findings underscore the need for effective preventive strategies, including immunization and early intervention.
DOI: 10.6084/m9.figshare.30894074.v1
title: Hospital burden of Respiratory Syncytial Virus in children in Spain (2016–2022): A retrospective study

description: Respiratory Syncytial Virus (RSV) is a leading cause of acute lower respiratory tract infections, particularly in children under two years of age. This study aimed to estimate the population-based burden of RSV-related hospitalizations in individuals under 19 y in Spain from 2016 to 2022. A retrospective analysis was conducted using national hospital discharge data. Hospitalization rates, mortality, case fatality, and associated healthcare costs were analyzed by age group and year. A total of 166,046 RSV-related hospitalizations were recorded (57.36% male), with 94.60% in children under 5 y and 66.22% in infants under 1 y. The highest mean hospitalization rate was observed in infants &lt;1 y (4,367.87 per 100,000), increasing to 5882.06 in 2022. Mortality was highest in infants &lt;1 y (2.9 per 100,000), while the highest case fatality rates occurred in the 10–14 (0.89%) and 15–19 (0.92%) age groups. Children &lt;5 y with comorbidities had significantly higher case fatality (0.76%) compared to those without (0.02%; OR=31.76). Hospitalization and mortality rates were lowest during the COVID-19 pandemic years. The mean cost per hospitalization was €3,169.63 for children &lt;5 y and €3,276.50 for infants &lt;1 y. The total cost exceeded €497 million, with €360 million attributed to infants &lt;1 y. RSV imposes a substantial burden on the pediatric population in Spain, particularly among infants. These findings underscore the need for effective preventive strategies, including immunization and early intervention.
DOI: 10.6084/m9.figshare.29502637
title: Use of bidirectional Mendelian randomization to unveil the association between antibody-mediated immune responses to infectious agents and allergic rhinitis

description: Allergic rhinitis (AR) is increasingly prevalent, yet diagnostic and therapeutic approaches remain inadequate. Recent studies show links between infectious diseases and noninfectious disorders, but the underlying mechanisms are largely unknown. We used bidirectional Mendelian randomization (MR) to investigate the impact of antibodies against infectious diseases on AR. Our results indicate that CMV IgG+, human herpesvirus 7 U14 antibodies, anti-varicella zoster virus IgG (VZV IgG+), and varicella zoster virus glycoproteins E/I antibodies are positively correlated with AR, while Epstein-Barr virus EBNA-1, ZEBRA, Merkel cell polyomavirus VP1, BK polyomavirus VP1, anti-human herpesvirus 6 E1A IgG, and human herpesvirus 6 IE1A antibodies are negatively correlated. Reverse MR analysis shows AR increases VZV IgG+ likelihood. These findings suggest a bidirectional causal relationship between infectious disease immune responses and AR, advancing understanding and potential diagnostics.
DOI: 10.6084/m9.figshare.29502637.v1
title: Use of bidirectional Mendelian randomization to unveil the association between antibody-mediated immune responses to infectious agents and allergic rhinitis

description: Allergic rhinitis (AR) is increasingly prevalent, yet diagnostic and therapeutic approaches remain inadequate. Recent studies show links between infectious diseases and noninfectious disorders, but the underlying mechanisms are largely unknown. We used bidirectional Mendelian randomization (MR) to investigate the impact of antibodies against infectious diseases on AR. Our results indicate that CMV IgG+, human herpesvirus 7 U14 antibodies, anti-varicella zoster virus IgG (VZV IgG+), and varicella zoster virus glycoproteins E/I antibodies are positively correlated with AR, while Epstein-Barr virus EBNA-1, ZEBRA, Merkel cell polyomavirus VP1, BK polyomavirus VP1, anti-human herpesvirus 6 E1A IgG, and human herpesvirus 6 IE1A antibodies are negatively correlated. Reverse MR analysis shows AR increases VZV IgG+ likelihood. These findings suggest a bidirectional causal relationship between infectious disease immune responses and AR, advancing understanding and potential diagnostics.
DOI: 10.6084/m9.figshare.30113508
title: The construction of a prognostic nomogram model for colorectal cancer and the prediction of immune characteristics and immune treatment responses based on the bioinformatics analysis of soluble mediator-related genes

description: Accurate prognosis prediction in colorectal cancer (CRC) is essential for personalized treatment. Soluble mediators are promising predictive biomarkers for evaluating outcomes. We sourced transcriptome data of CRC (COAD+READ) from TCGA and GEO. Soluble mediator-related genes (SMRGs) were identified via GeneCards. Through univariate Cox and Lasso regression analyses, prognosis-related feature genes were determined. A prognostic model was created using multivariate Cox regression, categorizing patients into high-risk (HR) and low-risk (LR) groups based on the median riskscore. KEGG pathway enrichment analysis and GSEA were undertaken on groups. ssGSEA assessed immune cell scores, while ESTIMATE analysis evaluated stromal and immune cell scores along with tumor purity. The CellMiner database identified potential drugs for HR patients. Pearson correlation analysis revealed the relationship between mismatch repair (MMR) genes and model genes. We identified 10 SMRGs. Pearson correlation analysis indicated positive correlations among these genes. GO analysis showed that most feature genes were linked to binding functions. KEGG analysis revealed that the HR group was enriched in pathways like Basal cell carcinoma and Glycosaminoglycan biosynthesis. The ssGSEA indicated higher immune cell scores in the LR group, alongside lower stromal scores. LR group also exhibited a lower TIDE score and higher immunophenoscore. Drug sensitivity analysis suggested PF-4708671, PI-103, and XAV939 as potential treatments for HR patients. There was significant correlation between model gene and MMR genes. The CRC prognostic model based on SMRGs effectively predicts patient prognosis and guides treatment strategies.
DOI: 10.6084/m9.figshare.30113508.v1
title: The construction of a prognostic nomogram model for colorectal cancer and the prediction of immune characteristics and immune treatment responses based on the bioinformatics analysis of soluble mediator-related genes

description: Accurate prognosis prediction in colorectal cancer (CRC) is essential for personalized treatment. Soluble mediators are promising predictive biomarkers for evaluating outcomes. We sourced transcriptome data of CRC (COAD+READ) from TCGA and GEO. Soluble mediator-related genes (SMRGs) were identified via GeneCards. Through univariate Cox and Lasso regression analyses, prognosis-related feature genes were determined. A prognostic model was created using multivariate Cox regression, categorizing patients into high-risk (HR) and low-risk (LR) groups based on the median riskscore. KEGG pathway enrichment analysis and GSEA were undertaken on groups. ssGSEA assessed immune cell scores, while ESTIMATE analysis evaluated stromal and immune cell scores along with tumor purity. The CellMiner database identified potential drugs for HR patients. Pearson correlation analysis revealed the relationship between mismatch repair (MMR) genes and model genes. We identified 10 SMRGs. Pearson correlation analysis indicated positive correlations among these genes. GO analysis showed that most feature genes were linked to binding functions. KEGG analysis revealed that the HR group was enriched in pathways like Basal cell carcinoma and Glycosaminoglycan biosynthesis. The ssGSEA indicated higher immune cell scores in the LR group, alongside lower stromal scores. LR group also exhibited a lower TIDE score and higher immunophenoscore. Drug sensitivity analysis suggested PF-4708671, PI-103, and XAV939 as potential treatments for HR patients. There was significant correlation between model gene and MMR genes. The CRC prognostic model based on SMRGs effectively predicts patient prognosis and guides treatment strategies.
DOI: 10.15468/dl.spcqzh
title: Occurrence Download

description: A dataset containing 59 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Sweden",
 "TaxonKey is Vulpes lagopus",
 "Year 1985-2005"
 ]
}

 The dataset includes 59 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0032016-260208012135463/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29357162
title: How should vaccine hesitancy be measured in healthcare workers? A systematic review of the measurement properties of validated tools

description: The use of validated tools to assess vaccine hesitancy is essential for designing strategies to improve vaccine uptake among healthcare workers (HCWs). This systematic review identified and evaluated tools measuring knowledge, attitudes, practices, vaccine intentions, and vaccine hesitancy in HCWs. Searches were conducted in PubMed, CINAHL, Scopus, Web of Science, PsycINFO, Cochrane Library, and JBI (PROSPERO: CRD42020212252). The methodological quality of the instruments was determined using the COnsensus-based Standards for the selection of health status Measurement Instruments (COSMIN) methodology. Of 11,580 articles screened, 33 studies were included, identifying 32 measurement tools related to vaccines recommended for HCWs, including influenza, HPV, HBV, and pertussis. The King’s Nurses Influenza Vaccination Questionnaire was the most frequently used and demonstrated reliable properties. Two other validated questionnaires showed adequate measurement properties. No validated tool was identified to comprehensively assess vaccine hesitancy across all HCW-recommended vaccines, limiting instrument applicability for broad implementation in healthcare settings.